Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 6/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 4/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 2/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19430089 | 0.91 | AOC3 (0.38) | AOC3WNK1ATRHCRTR1HCRTR2 | |
| SCHEMBL19429853 | 0.87 | AOC3 (0.41) | AOC3WNK1 | |
| SCHEMBL19430232 | 0.87 | AOC3 (0.40) | AOC3WNK1RAB9A | |
| SCHEMBL19430397 | 0.85 | AOC3 (0.48) | AOC3PRMT6 | |
| SCHEMBL19429867 | 0.85 | AOC3 (0.39) | AOC3WNK1PKM | |
| SCHEMBL19429872 | 0.83 | AOC3 (0.38) | AOC3PARP1WNK1 | |
| SCHEMBL19430288 | 0.83 | AOC3 (0.38) | AOC3PARP1PARP2WNK1RAB9A | |
| SCHEMBL19429963 | 0.82 | PRMT6 (0.37) | AOC3WNK1HCRTR1HCRTR2PRMT6 | |
| SCHEMBL19421666 | 0.82 | GBA1 (0.43) | AOC3PARP1WNK1ATRRAB9A | |
| SCHEMBL19430181 | 0.82 | AOC3 (0.38) | AOC3PRMT6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | AOC3 2654/4885PARP1 780/4885PARP2 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.